N
Normand Blais
Researcher at Université de Montréal
Publications - 160
Citations - 3287
Normand Blais is an academic researcher from Université de Montréal. The author has contributed to research in topics: Lung cancer & Cancer. The author has an hindex of 26, co-authored 137 publications receiving 2574 citations. Previous affiliations of Normand Blais include GlaxoSmithKline.
Papers
More filters
Journal ArticleDOI
Management of major bleeding complications and emergency surgery in patients on long-term treatment with direct oral anticoagulants, thrombin or factor-Xa inhibitors: proposals of the working group on perioperative haemostasis (GIHP) - March 2013.
Gilles Pernod,P. Albaladejo,Anne Godier,Charles Marc Samama,Sophie Susen,Yves Gruel,Normand Blais,Pierre Fontana,Ariel Cohen,Juan V. Llau,Nadia Rosencher,Jean-François Schved,Emmanuel de Maistre,Meyer Michel Samama,Patrick Mismetti,Pierre Sié +15 more
TL;DR: For urgent surgery with haemorrhagic risk, the drug plasma concentration should be less or equal to 30ng/mL for dabigatran and rivaroxaban and the administration of a procoagulant drug is discussed according to the NOAC concentration and the possibilities of mechanical haemostasis.
Journal ArticleDOI
Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea.
J. Maroun,Lowell Anthony,Normand Blais,Ronald Burkes,Scot D. Dowden,George Dranitsaris,B. Samson,A Shah,M. Thirlwell,Mark Vincent,R. Wong +10 more
TL;DR: Acute medical management of cid includes loperamide or diphenoxylate as first-line agents and hospitalization is recommended for patients with grades 3 and 4 cid; in-hospital care includes rehydration, antibiotic therapy, and octreotide.
Journal ArticleDOI
Dosage of enoxaparin among obese and renal impairment patients.
Annie Bazinet,Karine Almanric,Catherine Brunet,Isabel Turcotte,Josée Martineau,Stéphanie Caron,Normand Blais,Lyne Lalonde +7 more
TL;DR: Based on Anti-Xa, no dosage adjustments are required in obese patients and in renally impaired patients, adjustments may be necessary when enoxaparin is administered twice daily.
Journal ArticleDOI
Dacomitinib compared with placebo in pretreated patients with advanced or metastatic non-small-cell lung cancer (NCIC CTG BR.26): a double-blind, randomised, phase 3 trial.
Peter M. Ellis,Frances A. Shepherd,Michael Millward,Francesco Perrone,Lesley Seymour,Geoffrey Liu,Sophie Sun,Byoung Chul Cho,Alessandro Morabito,Natasha B. Leighl,Martin R. Stockler,Christopher W. Lee,Rafal Wierzbicki,Victor Cohen,Normand Blais,Randeep Sangha,Adolfo Favaretto,Jin Hyoung Kang,Ming-Sound Tsao,Carolyn F. Wilson,Zelanna Goldberg,Keyue Ding,Glenwood D. Goss,Penelope A. Bradbury +23 more
TL;DR: This study enrolled adults with advanced or metastatic non-small-cell lung cancer from 75 centres in 12 countries and randomly assigned 480 patients to dacomitinib and 240 patients to placebo, finding the effect of dAComit inib on overall survival seemed similar in patients with EGFR-mutation-positive tumours and EGFR wild-type tumours.
Journal ArticleDOI
A randomized phase II study of the telomerase inhibitor imetelstat as maintenance therapy for advanced non-small cell lung cancer
Alberto Chiappori,Tatjana Kolevska,David R. Spigel,Steven Hager,Mark U. Rarick,S. Gadgeel,Normand Blais,J. von Pawel,Lowell L. Hart,Martin Reck,Ekaterina Bassett,Bart Burington,Joan H. Schiller +12 more
TL;DR: Maintenance imetelstat failed to improve PFS in advanced NSCLC patients responding to first-line therapy, but there was a trend toward a improvement in median PFS and OS in patients with short TL.